An FDA clearance would bring Movano Health a significant step closer in its pursuit to disrupt the wearables industry while unlocking significant partnership opportunities. The Company continues to expect a decision regarding its 510(k) clearance in July 2024.
Save time and jump to the most important pieces.
Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto
New hardware boasts significant improvements to reduce noise and generate higher fidelity signals PLEASANTON, Calif., Nov. 7, 2024 /PRNewswire/ -- Movano Health Inc. (NASDAQ:MOVE) announced today that it has tested its newly developed blood pressure wrist wearable as part of its November 5th and 6th hypoxia clinical trial that took place at the University of California, San Francisco. The updated device features an additional 12 mmWave antennas which together with Movano Health's custom IC delivers enhanced data collection with less impact of placement while also featuring a slimmer design, making it easier and more comfortable to wear. In addition, the new wearable monitors a host of other
Company Continues to Work with Securities Regulators, Legal Advisors and Other Partners to Protect Interests of Shareholders PLEASANTON, Calif., Nov. 4, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) (the "Company") provided an update on an investigation to expose apparent manipulation in trading of the Company's common shares, following the recent announcement of a shareholder approved reverse stock split. Based on its preliminary investigation, the Company believes that between the announcement of the reverse split on October 25, 2024, and its effective date on October 2
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
4 - Movano Inc. (0001734750) (Issuer)
10-Q - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
8-K - Movano Inc. (0001734750) (Filer)
SC 13G - Movano Inc. (0001734750) (Subject)
SC 13G/A - Movano Inc. (0001734750) (Subject)
SC 13G - Movano Inc. (0001734750) (Subject)
Highlights successful Evie Ring back-in-stock execution Updates status of EvieMED 510(k) application review Focuses on launch of EvieMED and securing B2B opportunities Conference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Nov. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported third quarter 2024 results and provided a business update. The Company continues to remain focused on three key business initiatives. Successful execution of the Evie Ring direct-to-consumer business (D2C) following the September 17th back-in-sto
Prepares for September 17, 2024, Evie Ring back in stock dateAnnounces brand partnership with digital creator Heidi D'AmelioFocuses on launch of EvieMED and securing B2B opportunitiesConference Call at 2:00 PM PT/ 5:00 PM ET Today PLEASANTON, Calif., Aug. 14, 2024 /PRNewswire/ -- Movano Health (NASDAQ:MOVE), a pioneer in health technology, reported second quarter 2024 results and provided a business update. Following the successful close of the Company's April 2024 $24.1 million private placement that included a seed investment from a tier 1 multi-billion dollar medical device
Company continues to work with FDA to bring this pioneering healthcare product to market PLEASANTON, Calif., Aug. 5, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) plans to meet with the FDA in mid-August, as part of the Company's ongoing process to secure a 510(k) clearance for the EvieMED Ring, a wearable designed to not only provide medical device functionality through its pulse oximetry feature, but also offer numerous wellness metrics related to sleep, activity and mood/energy/symptom logging. On April 21, 2024, Movano Health filed an updated 510(k) for the EvieMED Ring's pulse oximetry feature. At the time of the filing and based on prior interactions with the agency and its protoco
Gainers Spectaire Holdings (NASDAQ:SPEC) stock moved upwards by 148.9% to $0.85 during Friday's pre-market session. The company's market cap stands at $15.6 million. Ascent Solar Technologies (NASDAQ:ASTI) stock rose 35.31% to $0.15. The market value of their outstanding shares is at $13.2 million. Sequans Communications (NYSE:SQNS) shares moved upwards by 14.46% to $0.55. The company's market cap stands at $34.0 million. The company's, Q1 earnings came out 3 days ago. Minim (NASDAQ:MINM) shares increased by 10.13% to $3.15. The market value of their outstanding shares is at $8.8 million. DatChat (NASDAQ:DATS) shares rose 8.15% to $1.34. The market value of their outstanding shares is a
Movano Health (Nasdaq: MOVE) announced major advances in the accuracy of its heart rate in motion algorithm following the implementation of deep learning into the processing. The Company recently released an engineering accuracy study directed by Movano Health Founder and CTO Michael Leabman, Enhanced Heart Rate in Motion Accuracy with the Evie Ring Using Advanced Deep Learning Algorithms, which demonstrates the value of deep learning integration into heart rate (HR) algorithms for improved accuracy.